Leerink Partners Begins Coverage on OnKure Therapeutics (NASDAQ:OKUR)

Analysts at Leerink Partners began coverage on shares of OnKure Therapeutics (NASDAQ:OKUR) in a report released on Thursday,Briefing.com Automated Import reports. The brokerage set an “outperform” rating and a $33.00 price target on the stock. Leerink Partners’ price target would suggest a potential upside of 132.72% from the company’s previous close.

Several other analysts have also recently weighed in on the stock. Lifesci Capital raised shares of OnKure Therapeutics to a “strong-buy” rating in a research note on Thursday, October 10th. Oppenheimer initiated coverage on shares of OnKure Therapeutics in a research report on Thursday, October 10th. They set an “outperform” rating and a $35.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $40.00 target price on shares of OnKure Therapeutics in a research report on Friday, November 8th.

OnKure Therapeutics Trading Down 3.1 %

Shares of OnKure Therapeutics stock opened at $14.18 on Thursday. The stock has a market cap of $47.36 million, a price-to-earnings ratio of -1.16 and a beta of 0.14. OnKure Therapeutics has a 1-year low of $9.80 and a 1-year high of $77.60.

OnKure Therapeutics (NASDAQ:OKUR) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.13). As a group, equities analysts anticipate that OnKure Therapeutics will post -4.21 EPS for the current year.

About OnKure Therapeutics

Reneo Pharmaceuticals Incis a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Incis based in SAN DIEGO.